147938-30-5

Basic information

• Product Name: N^α-<4-(methylamino)benzoyl>-N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester
• Synonyms: N^α-<4-(methylamino)benzoyl>-N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester
• CAS NO: 147938-30-5
• Molecular Weight: 607.578
• Mol File: 147938-30-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N^α-<4-(methylamino)benzoyl>-N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-<4-(methylamino)benzoyl>-N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester(147938-30-5)
• EPA Substance Registry System: N^α-<4-(methylamino)benzoyl>-N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester(147938-30-5)

Safety Data

• Hazardous Substances Data: 147938-30-5(Hazardous Substances Data)

Upstream product

• 56-85-9 L-glutamine 
• 147938-28-1 N^α--N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester 
• 110694-61-6 N--L-glutamine ethyl ester 
• 13726-85-7 Boc-Gln-OH 
• 147938-34-9 (S)-4-[2,2-Bis-(diethoxy-phosphoryl)-ethylcarbamoyl]-2-{4-[methyl-(2,2,2-trichloro-ethoxycarbonyl)-amino]-benzoylamino}-butyric acid ethyl ester 

Downstream Products

• 147938-31-6 N^α-<4-<(<2,4-diamino-6-pteridinyl>methyl)methylamino>benzoyl>-N^δ-<2,2-bis(diethylphosphono)ethyl>glutamine ethyl ester 

Relevant articles and documents

A study of the delivery-targeting concept applied to antineoplastic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues

With the aim of verifying the concept of osteotic vectorisation, synthesis of three methotrexate (MTX) gem-diphosphonic analogues (compounds A, B and C) was performed. These molecules were tested on BALB/c and NIH III mice previously grafted with subcutaneous implants of OHS, TTX p7 and/or TTX p11 human osteosarcoma cell lines. Antineoplasic activity of compound B and C (active compounds) was compared to the activity for MTX alone and to activity of compound A (inactive compound). Compounds B and C exhibited an increased antineoplasic activity compared to MTX alone and to compound A. At equimolar doses, compound B was found to be 5-6-fold more active than MTX given alone. We have discussed the concept of osteotic vectorisation of compound B, which could be regarded as a prodrug.